UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 31, 2024
Immunocore Holdings plc
(Exact name of registrant as specified in its Charter)
England and Wales
|
001-39992
|
Not Applicable
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
92 Park Drive,
Milton Park
Abingdon, Oxfordshire
United Kingdom
|
|
OX14 4RY |
(Address of principal executive offices)
|
|
(Zip Code)
|
+44 1235 438600
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange on which registered
|
American Depositary Shares, each representing one ordinary share, nominal value £0.002 per share
|
|
IMCR
|
|
The Nasdaq Stock Market LLC
|
Ordinary share, nominal value £0.002 per share*
|
|
*
|
|
The Nasdaq Stock Market LLC
|
* Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market LLC.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01. |
Regulation FD Disclosure.
|
On May 31, 2024, Immunocore Holdings plc (the “Company”) issued a press release announcing updated data from the Company’s Phase 1
clinical trial of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients. As disclosed in the press release, the Company is presenting such data at the 2024 American Society of
Oncology (ASCO) Annual Meeting on May 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
As discussed in the press release, the Company will host a conference call and live audio webcast today, May 31, 2024 at 7:15 p.m., Eastern Time, to discuss the Phase 1
PRAME expansion data and the Company’s Phase 3 registrational trial in cutaneous melanoma. The live audio webcast may be accessed through the “Events & Presentations” page in the “Investors” section of the Company’s website at
www.immunocore.com/investors.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is being furnished and
shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any of
the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by
specific reference in such filing.
Item 9.01. |
Financial Statements and Exhibits
|
|
Exhibit No.
|
|
Description
|
|
|
|
Press Release dated May 31, 2024.
|
|
104
|
|
Cover Page Interactive Data File (embedded within the Inline XBRL document).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
IMMUNOCORE HOLDINGS PLC
|
|
|
|
Dated: May 31, 2024
|
By:
|
/s/ Bahija Jallal, Ph.D.
|
|
|
|
Name:
|
Bahija Jallal, Ph.D.
|
|
|
Title:
|
Chief Executive Officer
|